( MENAFN - GlobeNewsWire - Nasdaq) Schoenefeld/Berlin, Germany, May 22, 2024 --- Captain T Cell GmbH , a biotechnology company developing next-generation T cells against solid tumors, today announced the successful closing of a seed financing round totaling € 8.5 million. A syndicate of experienced life science investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.
m.b.H participated in the round.
In addition, the German Federal Ministry of Education and Research (BMBF) is supporting the Company through its prestigious GO-Bio program. The financing also marks the appointment of biotech veteran Jörn Aldag as Chairman of the Board of Directors. The funds will be used to further progress Captain T Cell's first-in-class lead program towards the clinic along with a novel allogeneic platform for off-the-shelf treatments of solid tumors.
Captain T Cell develops first-in-class efficacy-enhanced TCR-T cells for solid tumors that are not addressed by existing therapies. Using a toolbox of next-generation technologies, Captain T Cell generates TCR-T cells with enhanced persistence and the capacity to cope with the hostile tumor microenvironment of difficult-to-treat solid tumors. In preclinical in vivo models, the Company has been able to completely eradicate aggressive tumors using these efficacy-enhanced T cells.
A key technology established by the Captain T Cell team is its proprietary TCR-ALLO platform for off-the-shelf treatment of solid tumor.
